Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151965 | 0.82 | SLC6A4 (0.59) | CYP19A1CYP11B1CYP11B2CYP1A2CYP2D6 | |
| SCHEMBL2071832 | 0.75 | CYP11B1 (1.00) | CYP19A1CYP11B1CYP11B2CYP3A4MAPT | |
| SCHEMBL6153431 | 0.73 | SLC6A4 (0.43) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4499181 | 0.70 | CYP11B1 (1.00) | CYP19A1CYP11B1CYP11B2CYP1A2CYP2D6 | |
| SCHEMBL6151910 | 0.69 | SLC6A4 (0.57) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL9194951 | 0.68 | FNTA (0.56) | CYP19A1CYP11B1CYP11B2MAPTFNTA | |
| SCHEMBL6152038 | 0.68 | SLC6A4 (0.58) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL6152051 | 0.68 | SLC6A4 (0.63) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL7211341 | 0.67 | SLC6A4 (0.56) | CYP2D6ALDH1A1HTR2ASLC6A4SLC6A2 | |
| SCHEMBL22114976 | 0.66 | IDO1 (0.64) | CYP19A1CYP11B1CYP11B2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | claimed |
| US-20020183306-A1 | Combination treatment for sleep disorders including sleep apnea | PFIZER INC. | 2002-12-05 | — | — | US | claimed |
| EP-1262197-A2 | Combination treatment for sleep disorders including sleep apnea | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| US-20020165217-A1 | Combination treatment for anxiety and depression | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1220831-B1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PROD INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| EP-1238676-B1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | disclosed |
| US-6596741-B2 | Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders. | PFIZER INC | 2003-07-22 | — | — | US | disclosed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1220831-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | Pfizer Products Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2001027068-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165217-A1 | Combination treatment for anxiety and depression | GABRA1, GABRA2, GABRA5 | CYP19A1 1017/4885CYP11B1 536/4885CYP11B2 563/4885 |
| US-20020183306-A1 | Combination treatment for sleep disorders including sleep apnea | HTR1A, HTR2A, ADRA2A | CYP19A1 849/4885CYP11B1 538/4885CYP11B2 377/4885 |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | CYP19A1 183/4885CYP11B1 297/4885CYP11B2 294/4885 |
| US-20040029972-A1 | Combination treatment for depression | HTR3A, HTR5A, HTR6 | CYP19A1 603/4885CYP11B1 555/4885CYP11B2 512/4885 |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | OPRM1, SLC6A2, OPRK1 | CYP19A1 1392/4885CYP11B1 471/4885CYP11B2 351/4885 |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | SLC6A3, OXTR, OPRD1 | CYP19A1 2230/4885CYP11B1 2196/4885CYP11B2 2063/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | CYP19A1 1640/4885CYP11B1 1079/4885CYP11B2 969/4885 |
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PMP22, GAP43, SLC6A2 | CYP19A1 3489/4885CYP11B1 689/4885CYP11B2 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.